RPost

We’re not just securing email and e-signing.

We’re helping ICON bring medicine to market faster, to help you and your loved ones live longer, healthier.

And we’ve been doing it with them since 2018.

RMail. For Life Sciences. Clinical Research.

  • Industry

Life Sciences

  • Sector

Clinical Research

  • Geography

Europe, Global

  • Platform

RMail®

Primary Use

Registered Email™ e-delivery proof with automatic encryption

Main Benefit

ICON implemented RMail® to improve compliance related to electronic clinical research notifications.

The distribution of safety reports and cover letters to investigators was a labor and cost-intensive process for ICON, a global provider of outsourced development and commercialisation services to the pharmaceutical, biotechnology and medical device industries. Thus, ICON implemented RMail to make its distribution system more efficient and SUSAR / SAE compliant. RMail helped ICON automate the complete process of delivering and tracking safety reports to investigators, CCMO, IRBs/IECs and other stakeholders, in a secure and audit-ready process. RMail delivered a quick return on investment by reducing labor, mailing and distribution costs, while providing proof of compliance to mitigate risk and speed clinical trials.

Automation

Sending application (Sage) automatically routes outbound messages of a certain type via REST APIs to RMail global processing networks, sending as encrypted Registered Email™ messages; and receiving via API the delivery audit trail forensics, status, and timestamps via the Registered Receipt™ proof record.

ICON is one of the world’s largest life sciences companies with specialty in clinical research. We’ve been providing assurance and proof that precise content of critical safety notices have been delivered to research investigators, with the urgency and proof of e-delivery required to minimize risk of re-occurrence of serious adverse health issues in clinical research processes.

Tradenames are owned by the named company. Service benefit is summary, not intended to be a case study. RPost technology is patented. RMail, RSign, and RPost are trademarks owned by RPost.